MILWAUKEE, Oct. 30, 2025 /PRNewswire/ -- The Society for Immunotherapy of Cancer (SITC) received an incredible number of abstract submissions in 2025, more than 1,300, including many clinical based ...

BERLIN--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor ...

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (ALXO),, an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our ...

CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that preclinical and clinical data supporting the ...

MARSEILLE, France--(BUSINESS WIRE)--#ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today three abstracts including Innate’s product candidates have ...

CAMBRIDGE, Mass., April 26, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the acceptance of clinical abstracts for multiple programs across its precision therapy ...

These clinical abstracts are courtesy of the organization WeMove (Worldwide Education and Awareness for Movement Disorders). Learn more about this group at their Web site: www.wemove.org. WeMove ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, today announced that the company and its collaborators will present a total of 26 abstracts ...

Nonsteroidal Anti-Inflammatory Drugs, Alone or Combined With Opioids, for Cancer Pain Brief description of the intervention, explicit identification of the primary end point, and presentation of ...